In development

Women's health is not just underfunded. It is under-translated.

Women's Health Foundry is a specialist national platform being developed by Proto Axiom to move more Australian women's health innovations from research into de-risked, investment-ready ventures and patient impact.

Backed by 33 investors including global business leaders.

Ecosystem momentum

Growing interest across Australia

Founders, researchers, partners, and investors are registering interest as the platform is developed.

The gap between discovery and patients is structural

Strong programs stall not because teams lack ambition, but because the next step is unclear: what to prove, in what sequence, to satisfy regulators, payers, and capital. Women's health ventures face particular complexity in endpoints, evidence standards, and adoption dynamics that generic programs rarely address.

Women's Health Foundry is being developed to close that gap: the expertise, capital, and commercial pathways needed to move research toward patients, not another open-ended grant round.

What makes this different

Five design choices that shape how the platform operates.

  • Specialist women's health focus

    Category-specific milestones, evidence sequencing, and partner networks built for how these assets actually progress.

  • Active incubation, not grant administration

    Hands-on support with decision-grade progress markers. Venture outcomes, not compliance paperwork.

  • Builder-operator model

    Proto Axiom designs and runs the platform: operating model, milestone logic, and execution. Not passive capital.

  • National, virtual-first structure

    Coordination and partner pathways not tied to a single building. In-person engagement where governance requires it.

  • Ecosystem integration

    Built with universities, health services, consumers, industry, and investors. Shared infrastructure, not a competing parallel track.

Operating model at a glance

Five linked stages from selection through partner and capital pathways.

Full model
  1. 01

    Source and select

    Screen for unmet need, evidence maturity, and credible venture potential.

  2. 02

    Stage 1 de-risking

    Fund work that removes the next material uncertainties: technical, regulatory, or commercial.

  3. 03

    Gate review

    Formal checkpoint: advance, change scope, or stop. No capital spent on drift.

  4. 04

    Stage 2 scale-up

    Deeper build: evidence plan, operating plan, team gaps, and partner-ready materials.

  5. 05

    Partner and capital pathways

    Curated introductions when timing, diligence, and governance align.

National in scope

Women's health innovation is distributed across Australian institutions. The platform is designed to reach and support teams nationally — not tied to a single city or campus.

New South Wales

University of Sydney, UNSW, Sydney Biomedical Accelerator. Primary infrastructure and clinical partner hub.

Victoria

Monash University, University of Melbourne, Royal Women's Hospital. Deep strength in reproductive biology and maternal health.

Queensland

University of Queensland, QIMR Berghofer. Emerging programs in fertility research and clinical trials.

National network

Virtual-first coordination with in-person engagement where governance requires it. Partner pathways across SA, WA, TAS, and ACT institutions.

Partner institutions and state-level engagement are being finalised. The platform is designed for national reach from day one.

What founders receive

Concrete support structured around the recurring failure modes inwomen's health venture translation.

For founders
  • Milestone funding

    Capital tied to defined de-risking steps, not undifferentiated runway.

  • Regulatory planning

    Early mapping of classification, evidence expectations, and pathway risk.

  • Clinical trial design

    Endpoint and study-shape choices matched to what investors and regulators care about next.

  • Commercial strategy

    Who pays, how adoption happens, and what has to be true for the economics to work.

  • Mentor and advisory access

    Structured access to people who have shipped in this category, not generic coaching.

  • Follow-on capital support

    Positioning and introductions toward the next financing round when milestones warrant it.

Community in action

Building the ecosystem before the platform

Proto Axiom has been actively convening researchers, investors, and institutions around Australian biotech translation — creating the relationships and infrastructure that Women's Health Foundry is designed to scale.

Full track record

$750K+

Researcher grants awarded

300+

Investors and clinicians convened

14

Live pitches at Pitch for Health 2026

2

Institutional co-hosts

Challenger Summit · 2024

National biotech pitch event

$250,000 in grants to early-stage researchers. Ten finalists from universities across Australia and New Zealand pitched to venture capitalists, industry leaders, and philanthropists.

Pitch for Health · March 2026

Co-hosted with St Vincent's Curran Foundation

Australia's largest medical and biotech pitch day. $500,000 in grants across two streams, with 300+ investors, clinicians, and industry leaders in Sydney.

AusBiotech · 2026

Women's health translation program

Co-designed joint program with Australia's peak biotech industry body, running August–September 2026 with initial emphasis on translational innovation in women's health.

Confirmed partnership

AusBiotech joint program

Proto Axiom and AusBiotech — Australia's peak biotechnology industry body representing 3,000+ members — are co-designing a joint program focused on translational innovation in women's health, running August–September 2026.

The program will connect researchers and early ventures with industry partners, regulatory expertise, and capital pathways through AusBiotech's national network — reinforcing the platform's commitment to building with the ecosystem, not alongside it.

Program structure and participation details will be announced when confirmed.

The ecosystem

Organisations working in this space

Australian universities, health systems, and industry bodies are active in women's health research and translation. Proto Axiom has worked with several of these institutions and continues to build relationships across the ecosystem.

University of SydneyUNSWMonash UniversitySt Vincent’s HospitalSydney Biomedical Accelerator

These are organisations active in the Australian health and life sciences ecosystem. Listing does not imply formal partnership or endorsement of the platform.

Register interest

Tell us your role and context. We use this to prioritise outreach as the platform is finalised.

Founders / researchers

Share stage and institution so we can route you appropriately.

Read for founders

Partners / advisors

Signal how you can contribute: sites, expertise, or networks.

Read for partners

Investors / supporters

Register for updates on pipeline and platform milestones.

Read FAQ